CEMI News and Press, Chembio Diagnostics Inc. From 05/31/22

3 Penny Stocks to Add to Your Watchlist This Month With another day of trading penny stocks over, there is a lot to be excited about. Over the past week, we have seen some major stock market movements. While this can lead to large losses, it can also lead to very sizable gains. To under...

HAUPPAUGE, N.Y., May 24, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Chembio) (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced the election of Leslie Teso-Lichtman to its Board of Directors at Chembio’s 2022 ...

Chembio Diagnostics (NASDAQ:CEMI) signed an agreement under which Reszon Diagnostics International will manufacture its HIV 1/2 STAT-PAK Assay products in the Chembio Diagnostics Malaysia facility, which had previously suspended operations in May 2020. Operations are planned to begi...

Chembio Diagnostics press release (NASDAQ:CEMI): Q1 GAAP EPS of -$0.29 misses by $0.08. Revenue of $18.82M (+115.8% Y/Y) beats by $7.02M. For further details see: Chembio Diagnostics GAAP EPS of -$0.29 misses by $0.08, revenue of $18.82M beats by $7.02M

HAUPPAUGE, N.Y., May 05, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (“Chembio” or the “Company”) (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter ended March 31, 2...

HAUPPAUGE, N.Y., April 21, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the first quarter of 2022 after the close of trading on Thursd...

Chembio Diagnostics, Inc. (CEMI) Q4 2021 Earnings Conference Call March 3, 2022, 4:30 PM ET Company Participants Richard Eberly – President & Chief Executive Officer Larry Steenvoorden – Chief Financial Officer Philip Taylor – Investor Relations Conference Call Partic...

Chembio Diagnostics press release (NASDAQ:CEMI): Q4 GAAP EPS of $0.47 beats by $0.67. Revenue of $20.6M (+101.6% Y/Y) beats by $7.05M. For further details see: Chembio Diagnostics GAAP EPS of $0.47 beats by $0.67, revenue of $20.6M beats by $7.05M

HAUPPAUGE, N.Y., March 03, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (“Chembio” or the “Company”) (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter and year ended ...

Chembio Diagnostics (NASDAQ:CEMI) is scheduled to announce Q4 earnings results on Thursday, March 3rd, after market close. The consensus EPS Estimate is -$0.20 (+42.9% Y/Y) and the consensus Revenue Estimate is $13.55M (+32.6% Y/Y). Over the last 1 year, CEMI has beaten EPS estimates 25% of t...